milvexian
bms
['factor xi', 'axiomatic', 'milvexian']
late-breaking results from phase 2 axiomatic-ssp study of milvexian, an investigational oral factor xia inhibitor, show favorable antithrombotic profile in combination with dual antiplatelet therapy 
Breaking news from Business Wire